Low intensity focused ultrasound (LIFU) triggered drug release from cetuximab-conjugated phase-changeable nanoparticles for precision theranostics against anaplastic thyroid carcinoma

Wei, Xiawei; Sui, Guoqing; Teng, Dengke; Wang, Qimeihui; Qu, Jia; Zhu, Lingyu; Ran, Haitao; Wang, Zhigang; Jin, Chunxiang; Wang, Hui

doi:10.1039/c8bm00970h

Cited by 29 publications

(29 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was also possible to image the droplets before activation using B-mode and contrast-enhanced ultrasound imaging, which can be seen in Figure 3. These results are similar to those obtained by Wang et al [87]. They developed a biocompatible cetuximab-conjugated phase-change capsules (H-CPN) that resulted in a cell viability for C643 cells of 23.5% ± 1.29% after 3 minutes of LIFU exposure, in comparison with a cell viability of 31.09% ± 1.57% for free 10-HCPT.…”

Section: Applications Of Acoustic Droplet Vaporizationsupporting

confidence: 89%

Review on Acoustic Droplet Vaporization in Ultrasound Diagnostics and Therapeutics

Loskutova

Grishenkov

Ghorbani

2019

BioMed Research International

View full text Add to dashboard Cite

Acoustic droplet vaporization (ADV) is the physical process in which liquid undergoes phase transition to gas after exposure to a pressure amplitude above a certain threshold. In recent years, new techniques in ultrasound diagnostics and therapeutics have been developed which utilize microformulations with various physical and chemical properties. The purpose of this review is to give the reader a general idea on how ADV can be implemented for the existing biomedical applications of droplet vaporization. In this regard, the recent developments in ultrasound therapy which shed light on the ADV are considered. Modern designs of capsules and nanodroplets (NDs) are shown, and the material choices and their implications for function are discussed. The influence of the physical properties of the induced acoustic field, the surrounding medium, and thermophysical effects on the vaporization are presented. Lastly, current challenges and potential future applications towards the implementation of the therapeutic droplets are discussed.

show abstract

Section: Applications Of Acoustic Droplet Vaporizationsupporting

confidence: 89%

Review on Acoustic Droplet Vaporization in Ultrasound Diagnostics and Therapeutics

Loskutova

Grishenkov

Ghorbani

2019

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…However, the cell viability inhibition of FA-FCP + LIFU was significantly higher than that of FP + LIFU, FCP + LIFU and FA-FCP without LIFU, indicating that FA-FCP combined with LIFU irradiation offered better anti-tumor efficiency. This result was mainly due to the presence of LIFU and the acid environment of the lysosome, both of which could induce the drug release and cavitation effect, and the FA-mediated tumor cells target effect [36][37][38].…”

Section: In Vitro and In Vivo Anticancer Therapymentioning

confidence: 99%

Curcumin-Loaded Nanoparticles with Low-Intensity Focused Ultrasound-Induced Phase Transformation as Tumor-Targeted and pH-Sensitive Theranostic Nanoplatform of Ovarian Cancer

et al. 2020

View full text Add to dashboard Cite

We have developed a simple and versatile nanoplatform using pH-sensitive ferritin nanocages co-loaded with the anticancer drug curcumin (Cur) and liquid fluorocarbon perfluorohexane (PFH) inside the core and conjugated tumor-targeting molecule FA outside the shell referred to as FA-FCP. The synthesized FA-FCP has an average particle diameter of 47 nm, with stable and favorable physicochemical properties in different media, and high biocompatibility and biosafety in vivo and in vitro. Under the conditions of low-intensity focused ultrasound (LIFU) and at pH = 5.0, FA-FCP released a large amount of drugs (53.2%) in 24 h. After 4 min of LIFU (7 W) treatment, FA-FCP provided contrast-enhanced ultrasound imaging capabilities at pH = 5.0. Due to FA receptor-mediated endocytosis, FA-FCP could efficiently enter the cells and further relocate to lysosomes. Eighteen hours after injection of FA-FCP, the tumor was stimulated by LIFU, resulting in a contrast-enhanced ultrasound image. In vivo and in vitro experiments showed that the combined use of FA-FCP and LIFU had significant tumor treatment effects. Based on the results, it was concluded that FA-FCP combined with the external LIFU and the endogenic acidic environment can have powerful theranostic functions and provide a novel type of non-invasive and integrated tumor theranostic option.

show abstract

“…In vitro release studies were performed using the dialysis bag method as reported. [ 28 ] HCaM‐PB and HSiM‐PB were added into a dialysis bag and placed in PBS solution (pH 7.4) for the first 12 h and in PBS (pH 5.0) for another 60 h at a rotation speed of 120 rpm min −1 and a temperature of 37 °C. At the predetermined time points, 1 mL of supernatant was taken and the cumulative drug release was determined by HPLC.…”

Section: Methodsmentioning

confidence: 99%

Smart Tumor Microenvironment‐Responsive Nanotheranostic Agent for Effective Cancer Therapy

Guo

Sun

et al. 2020

Adv Funct Materials

View full text Add to dashboard Cite

The tumor microenvironment (TME), which includes acidic and hypoxic conditions, severely impedes the therapeutic efficacy of antitumor agents. Herein, MnO 2 -loaded, bovine serum albumin, and PEG co-modified mesoporous CaSiO 3 nanoparticles (CaM-PB NPs) are developed as a nanoplatform with sequential theranostic functions for the engineering of TME. The MnO 2 NPs generate O 2 in situ by reacting with endogenous H 2 O 2 , relieving the hypoxic state of the TME that further modulates the cancer cell cycle status to S phase, which improves the potency of co-loaded S phase-sensitive chemotherapeutic drugs. After the hypoxia relief, CaM-PB can sustainably release drugs due to the enlarged pores of mesoporous CaSiO 3 in the acidic TME, preventing the drug pre-leakage into the blood circulation and insufficient drug accumulation at tumor sites. Moreover, the Mn 2+ released from the MnO 2 NPs at tumor sites can potentially serve as a diagnostic agent, enabling the identification of tumor regions by T 1 -weighted magnetic resonance imaging during therapy. In vivo pharmacodynamics results demonstrate that these synergetic effects caused by CaM-PB NPs significantly contribute to the inhibition of tumor progression. Therefore, the CaM-PB NPs with sequential theranostic functions are a promising system for effective cancer therapy. Keywordshypoxia relief, mesoporous calcium silicate, sequential functions, sustained drug release, synergetic effects

show abstract

Low intensity focused ultrasound (LIFU) triggered drug release from cetuximab-conjugated phase-changeable nanoparticles for precision theranostics against anaplastic thyroid carcinoma

Abstract: This study provides an efficient theranostic strategy for concurrent targeted ultrasound molecular imaging and effective synergistic antitumor therapy.

Cited by 29 publications

References 74 publications

Review on Acoustic Droplet Vaporization in Ultrasound Diagnostics and Therapeutics

Review on Acoustic Droplet Vaporization in Ultrasound Diagnostics and Therapeutics

Curcumin-Loaded Nanoparticles with Low-Intensity Focused Ultrasound-Induced Phase Transformation as Tumor-Targeted and pH-Sensitive Theranostic Nanoplatform of Ovarian Cancer

Smart Tumor Microenvironment‐Responsive Nanotheranostic Agent for Effective Cancer Therapy

Contact Info

Product

Resources

About